1) Patent Filings at Aurigene : Link

2) List of publications/ posters

• Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway  presented at AACR Annual Meeting, March31 – April 4, 2012, Chicago, IL

• Auirgene -012 as a novel peptide inhibitor of the PD1 signalling pathway_ Identification of a preclinical drug candidate for cancer therapy  presented at “Natural Peptides to Drugs, 5^th International Congress, December 4 – 7 2011, Zermatt, Switzerland”

• Demonstration of anti-tumor efficacy in Multiple preclinical cancer models using Aurigene’s PD-1 inhibitor presented at 6^th Annual peptide Therapeutics Symposium, Oct 20-21 2011,  La Jolla, CA

• Peptide hormone isoforms: N- terminally branched PYY3–36 isoforms give improved lipid and fat-cell metabolism in diet-induced obese mice: JPS 2010

• Evaluation of Potent Small Molecules Inhibitors of Capsase-3 : Aurigene_Caspase3_full poster

• Development of DPP IV Inhibitors presented at IBC Conference on Drug Discovery to Clinical Trials, Mumbai, India (Oct 5-7, 2005) 

• Peptide Architecture: Adding an a-Helix to the PYY Lysine Side Chain Provides Nanomolar Binding and Body Weight Lowering Effects published in ChemMedChem’2010